Insights: PODCASTing
Lab medicine is an ever-evolving field, and staying up to date can be a challenge. Mayo Clinic Laboratories' podcasts are designed to share the information you need to know about the latest developments in laboratory diagnostics.
Most recent posts
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, welcomes William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, to explore recent news updates and key advancements shaping the industry in 2025.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Vanda Lennon, M.D., Ph.D., founder of the Neuroimmunology Laboratory and now director of the Neuroimmunology Research Laboratory at Mayo Clinic. Dr. Pritt and Dr. Lennon discuss the research and testing innovations that have led to critical advancements in the field of autoimmune neurology over the last few decades.
In this test-specific episode of the "Answers From the Lab" podcast, Wei Shen, Ph.D., explains how Mayo Clinic Laboratories' new breast cancer panel provides rapid results to guide critical decisions about treatment and screening.
In this episode of Mayo Clinic Laboratories’ “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, talks with quality management coordinator Kate Pearce about optimizing preanalytic quality for specimens received from outreach laboratory customers.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Dr. Bradley Erickson, Director of the Mayo Clinic Artificial Intelligence Lab, and professor of Radiology at Mayo Clinic, to talk about working with artificial intelligence and how to train on it.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, and Elitza Theel, Ph.D., director of the Infectious Diseases Serology Laboratory at Mayo Clinic, talk about dengue and chikungunya arboviral infections.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' gynecological NGS panels provide focused assessments of gynecological cancers. The cost-effective tests fill the gap between single gene assays and large cancer panels, to inform prognosis and treatment.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss locally acquired cases of malaria that have recently occurred in Texas and Florida.
Sounak Gupta, M.B.B.S., Ph.D., explains how Mayo Clinic Laboratories' urologic panels efficiently inform prognosis and individualized cancer treatment. The carefully curated panels fill the void between single gene assays and large NGS panels.
In this episode of “Lab Medicine Rounds,” Justin Kreuter, M.D., sits down with Clarissa Jordan, M.D., chief resident in anatomic and clinical pathology for the Department of Laboratory Medicine and Pathology at Mayo Clinic, to discuss online pathology resources.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., director of the Clinical Virology Laboratory at Mayo Clinic, to discuss why measles prevention continues to be critically important.
John Lieske, M.D., explains why it's now easier for clinicians to pull information from Mayo Clinic Laboratories' supersaturation test report. An updated format summarizes complex information to help guide the treatment of kidney stones.
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Department of Laboratory Medicine and Pathology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest update on the U.S. Food and Drug Administration’s (FDA) proposed rule to oversee laboratory-developed tests (LDTs) and what that could mean for laboratories.





